CEO Christophe Weber to retire from Takeda in June 2026 after 12 years; Julie Kim, president of the U.S. Business Unit, named to succeed Weber after multi-year succession process ...

Takeda Pharmaceutical named Julie Kim, who heads its U.S. business, as its new chief executive starting in 2026, elevating her to the small but growing ranks of women leading Japanese companies.

Takeda Pharmaceutical raised its annual earnings forecasts despite posting lower quarterly net profit, and it said Julie Kim, who heads its U.S. business unit, will become chief executive in 2026.

Julie Kim was promoted to president of the U.S. business unit of Takeda after three years heading up the company's plasma-derived therapies division. She has been named a 2022 honoree of the BBJ's ...

Takeda employees, including Julie Kim, president of Takeda's U.S. Business Unit, volunteering with local nonprofit Community Servings. Liz Linder By Meera Raman – Reporter, Boston Business Journal ...

In a second appointment this week, Takeda named Julie Kim, its plasma-derived therapies business head, its next leader of the key U.S. business. Thirdly, Takeda is making Gabriele Ricci its next ...

OSAKA, Japan & CAMBRIDGE, Mass., January 30, 2025--Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president ...

OSAKA, Japan & CAMBRIDGE, Mass., January 30, 2025--Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of ...

Takeda(TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S. Business Unit, as the successor ...

Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S. Business Unit, as the successor ...